Allogene Therapeutics ALLO Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's unrealized losses on investments (before tax)?
- Allogene Therapeutics (ALLO) reported unrealized losses on investments (before tax) of $249K in Q1 2026.
- How has Allogene Therapeutics's unrealized losses on investments (before tax) changed year-over-year?
- Allogene Therapeutics's unrealized losses on investments (before tax) increased by 154.1% year-over-year, from $98K to $249K.
- What is the long-term trend for Allogene Therapeutics's unrealized losses on investments (before tax)?
- Over 5 years (2020 to 2025), Allogene Therapeutics's unrealized losses on investments (before tax) has grown at a -28.4% compound annual growth rate (CAGR), from $53K to $10K.